CoChat

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

Open access

The DOI matches its Crossref record; 75 of the 76 references it cites were found in a registry or an index.

Abstract

Abstract Background Immune checkpoint inhibition and in particular anti-PD-1 immunotherapy have revolutionized the treatment of advanced melanoma. In this regard, higher tumoral PD-L1 protein (gene name: CD274) expression is associated with better clinical response and increased survival to anti-PD-1 therapy. Moreover, there is increasing evidence that tumor suppressor proteins are involved in immune regulation and are capable of modulating the expression of immune checkpoint proteins. Here, we determined the role of p53 protein (gene name: TP53) in the regulation of PD-L1 expression in melanoma. Methods We analyzed publicly available mRNA and protein expression data from the cancer genome/proteome atlas and performed immunohistochemistry on tumors with known TP53 status. Constitutive and IFN-ɣ-induced PD-L1 expression upon p53 knockdown in wildtype, TP53-mutated or JAK2-overexpressing melanoma cells or in cells, in which p53 was rendered transcriptionally inactive by CRISPR/Cas9, was determined by immunoblot or flow cytometry. Similarly, PD-L1 expression was investigated after overexpression of a transcriptionally-impaired p53 (L22Q, W23S) in TP53-wt or a TP53-knockout melanoma cell line. Immunoblot was applied to analyze the IFN-ɣ signaling pathway. Results For TP53-mutated tumors, an increased CD274 mRNA expression and a higher frequency of PD-L1 positivity was observed. Interestingly, positive correlations of IFNG mRNA and PD-L1 protein in both TP53-wt and -mutated samples and of p53 and PD-L1 protein suggest a non-transcriptional mode of action of p53. Indeed, cell line experiments revealed a diminished IFN-ɣ-induced PD-L1 expression upon p53 knockdown in both wildtype and TP53-mutated melanoma cells, which was not the case when p53 wildtype protein was rendered transcriptionally inactive or by ectopic expression of p53L22Q,W23S, a transcriptionally-impaired variant, in TP53-wt cells. Accordingly, expression of p53L22Q,W23S in a TP53-knockout melanoma cell line boosted IFN-ɣ-induced PD-L1 expression. The impaired PD-L1-inducibility after p53 knockdown was associated with a reduced JAK2 expression in the cells and was almost abrogated by JAK2 overexpression. Conclusions While having only a small impact on basal PD-L1 expression, both wildtype and mutated p53 play an important positive role for IFN-ɣ-induced PD-L1 expression in melanoma cells by supporting JAK2 expression. Future studies should address, whether p53 expression levels might influence response to anti-PD-1 immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13046-019-1403-9

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 TP53-mutated melanoma show higher CD274 mRNA expression levels, and are immunohistochemically more often PD-L1 positive. a Analysis of TCGA melanoma samples (n = 347) for differences in CD274 mRNA expression. Wilcoxon-Mann-Whitney test was used to compare CD274 expression between TP53-wt and -mutant samples. b PD-L1 immunohistochemistry of primary and metastatic melanoma samples (n = 81). Next-generation sequencing of the TP53 gene was performed previously. Samples harboring more than > 1% PD-L1 positive melanoma cells were regarded as PD-L1-positive. A PD-L1 negative, and a positive metastasis are depicted. Magnification, each 400x (c, d) Samples (n = 262) were stratified by TP53-mutation status and publicly available PD-L1 expression determined by reverse phase protein array was compared with the Wilcoxon-Mann-Whitney test (c) and by linear regression association analysis with p53 (d). mRNA and protein data are presented on a logarithmic scale. p < 0.05 is regarded as statistically significant. TPM, transcripts per million; wt, wildtype; mut, mutation
Fig. 1 TP53-mutated melanoma show higher CD274 mRNA expression levels, and are immunohistochemically more often PD-L1 positive. a Analysis of TCGA melanoma samples (n = 347) for differences in CD274 mRNA expression. Wilcoxon-Mann-Whitney test was used to compare CD274 expression between TP53-wt and -mutant samples. b PD-L1 immunohistochemistry of primary and metastatic melanoma samples (n = 81). Next-generation sequencing of the TP53 gene was performed previously. Samples harboring more than > 1% PD-L1 positive melanoma cells were regarded as PD-L1-positive. A PD-L1 negative, and a positive metastasis are depicted. Magnification, each 400x (c, d) Samples (n = 262) were stratified by TP53-mutation status and publicly available PD-L1 expression determined by reverse phase protein array was compared with the Wilcoxon-Mann-Whitney test (c) and by linear regression association analysis with p53 (d). mRNA and protein data are presented on a logarithmic scale. p < 0.05 is regarded as statistically significant. TPM, transcripts per million; wt, wildtype; mut, mutationCC BY · PubMed Central
Fig. 2 CD274 expression correlates with genes of immune-related pathways while PD-L1 levels lack correlation with p53’s transcriptional activity. a Immunoblot for PD-L1 and p53 expression of each six untreated TP53-wildtype and -mutated melanoma cell lines. Before lysis, cells were cultured for at least three days. Blot is representative of two individual experiments. b Correlation of CD274 with other genes was calculated using Spearman correlation (n = 447). Only genes with > 1 TPM in a least 20% of cases were included. The 24 best correlating genes are presented in a “heatmap”. Expression values are presented in a spectrum of blue (small) to red (high). c Gene enrichment analysis of the 24 best correlating genes with PANTHER overrepresentation test and Fisher test statistics depicting overrepresented pathways. Total number (#) of genes ascribed to the respective pathway, number of genes from the top 24 genes belonging to the pathway, expected frequency, fold enrichment, overpresentation indicated by “+”, raw p-value and false discovery rate (FDR) are given. p < 0.05 is regarded as statistically significant. TPM, transcripts per million
Fig. 2 CD274 expression correlates with genes of immune-related pathways while PD-L1 levels lack correlation with p53’s transcriptional activity. a Immunoblot for PD-L1 and p53 expression of each six untreated TP53-wildtype and -mutated melanoma cell lines. Before lysis, cells were cultured for at least three days. Blot is representative of two individual experiments. b Correlation of CD274 with other genes was calculated using Spearman correlation (n = 447). Only genes with > 1 TPM in a least 20% of cases were included. The 24 best correlating genes are presented in a “heatmap”. Expression values are presented in a spectrum of blue (small) to red (high). c Gene enrichment analysis of the 24 best correlating genes with PANTHER overrepresentation test and Fisher test statistics depicting overrepresented pathways. Total number (#) of genes ascribed to the respective pathway, number of genes from the top 24 genes belonging to the pathway, expected frequency, fold enrichment, overpresentation indicated by “+”, raw p-value and false discovery rate (FDR) are given. p < 0.05 is regarded as statistically significant. TPM, transcripts per millionCC BY · PubMed Central
Fig. 3 Presence of p53 protein, but not its transcriptional activity determines extent of IFN-ɣ induced PD-L1 expression in melanoma. a Immunoblot for PD-L1 and p53. NSCLC cell lines A549 and H460 served as control; all other are melanoma cell lines. IFN-ɣ treatment was for 48 h. b p53 was rendered transcriptionally inactive by introducing deletions using CRISPR/Cas9 technology and gRNA targeting exons 7 and 9 (LOX-IMVI) or exons 8 and 9 (UACC-62), respectively. Loss of transcriptional activity was determined by expression of GFP-based p53 reporter (left histograms; red: parental cells; blue: cells after CRISPR/Cas9 genome editing). Protein expression of p53 and PD-L1 in the absence or presence of IFN-ɣ for 48 h was determined by immunoblot. c Immunoblot for PD-L1 and p53 in TP53-mutated melanoma cells upon shRNA-mediated p53 knockdown. Cells were treated with IFN-ɣ as their TP53-wildtyp counterparts described in (a). p53 knockdown was achieved by culturing cells in doxycycline for 6 days. d, e Two TP53-wt melanoma cell lines (d) or a TP53-knockout cell line (e) were transduced with doxycycline-inducible p53L22Q,W23S expression construct. Cells were incubated with doxycycline and treated with IFN-ɣ for 48 h, as described before. Expression of indicated proteins was determined by immunoblot. Arrow (d) indicates ectopic p53 expression. Please note, that for M19-MEL (d) the ectopic p53 expression was so much stronger than the endogenous that, in those samples without doxycycline, the signal for endogenous p53 was too low to be detected. ß-tubulin (a-d) or actin (e) served as loading controls. DOX, doxycycline. All blots are representative of two individual experiments
Fig. 3 Presence of p53 protein, but not its transcriptional activity determines extent of IFN-ɣ induced PD-L1 expression in melanoma. a Immunoblot for PD-L1 and p53. NSCLC cell lines A549 and H460 served as control; all other are melanoma cell lines. IFN-ɣ treatment was for 48 h. b p53 was rendered transcriptionally inactive by introducing deletions using CRISPR/Cas9 technology and gRNA targeting exons 7 and 9 (LOX-IMVI) or exons 8 and 9 (UACC-62), respectively. Loss of transcriptional activity was determined by expression of GFP-based p53 reporter (left histograms; red: parental cells; blue: cells after CRISPR/Cas9 genome editing). Protein expression of p53 and PD-L1 in the absence or presence of IFN-ɣ for 48 h was determined by immunoblot. c Immunoblot for PD-L1 and p53 in TP53-mutated melanoma cells upon shRNA-mediated p53 knockdown. Cells were treated with IFN-ɣ as their TP53-wildtyp counterparts described in (a). p53 knockdown was achieved by culturing cells in doxycycline for 6 days. d, e Two TP53-wt melanoma cell lines (d) or a TP53-knockout cell line (e) were transduced with doxycycline-inducible p53L22Q,W23S expression construct. Cells were incubated with doxycycline and treated with IFN-ɣ for 48 h, as described before. Expression of indicated proteins was determined by immunoblot. Arrow (d) indicates ectopic p53 expression. Please note, that for M19-MEL (d) the ectopic p53 expression was so much stronger than the endogenous that, in those samples without doxycycline, the signal for endogenous p53 was too low to be detected. ß-tubulin (a-d) or actin (e) served as loading controls. DOX, doxycycline. All blots are representative of two individual experimentsCC BY · PubMed Central
Fig. 4 Correlation of STAT1 and CD274/PD-L1 in melanoma, and disturbed IFN-ɣ signaling upon p53 knockdown in melanoma cell lines. a, b Linear regression analyses of STAT1 mRNA with CD274 mRNA (n = 347) (a) or PD-L1 protein (n = 262) (b). c LOX-IMVI and M19-MEL were incubated in six well plates for 6 days with doxycycline for p53 knockdown and subsequently treated with IFN-ɣ for 5, 15, 30 or 60 min. Effect of treatment on the IFN-ɣ signaling pathway was analyzed by immunoblot with the indicated antibodies. ß-tubulin served as a loading control. p < 0.05 is regarded as statistically significant. DOX, doxycycline; TPM, transcripts per million
Fig. 4 Correlation of STAT1 and CD274/PD-L1 in melanoma, and disturbed IFN-ɣ signaling upon p53 knockdown in melanoma cell lines. a, b Linear regression analyses of STAT1 mRNA with CD274 mRNA (n = 347) (a) or PD-L1 protein (n = 262) (b). c LOX-IMVI and M19-MEL were incubated in six well plates for 6 days with doxycycline for p53 knockdown and subsequently treated with IFN-ɣ for 5, 15, 30 or 60 min. Effect of treatment on the IFN-ɣ signaling pathway was analyzed by immunoblot with the indicated antibodies. ß-tubulin served as a loading control. p < 0.05 is regarded as statistically significant. DOX, doxycycline; TPM, transcripts per millionCC BY · PubMed Central
Fig. 5 Restoration of p53 knockdown-associated JAK2 downregulation improves IFN-ɣ-inducible PD-L1 expression. a Immunoblot of three melanoma cell lines containing either an inducible TP53-targeting or a scr shRNA expression vector. IFN-ɣ treatment was for 48 h. b, c Linear regression analyses of JAK2 mRNA with CD274 mRNA (b; n = 347) or PD-L1 protein (c; n = 262). d M19-MEL and UACC-62 cells containing an inducible TP53-targeting shRNA vector were treated for 6 days with doxycycline with the last 2 days either in absence or presence of IFN-ɣ. After RNA isolation and cDNA generation, real-time quantitative PCR was performed for determination of TP53, JAK2 and CD274 mRNA expression. Relative expressions were calculated by the ΔΔCq method to the respective cell line sample without doxycycline and IFN-ɣ treatment. After log2 transformation, the means + SD of three independent experiments are depicted. Significant differences are indicated by stars (* < 0.05; ** < 0.01; paired t-test). e Two melanoma cell lines containing Doxycycline-inducible p53 shRNA were transduced with a JAK2 expression construct. Control cells and JAK2-overexpressing cells were incubated with doxycycline and treated with IFN-ɣ for 48 h as described before. Expression of indicated proteins was determined by immunoblot. ß-tubulin served as a loading control. p < 0.05 is regarded as statistically significant. DOX, doxycycline; scr, scramble; TPM, transcripts per million, ctrl, control. All blots are representative of two individual experiments
Fig. 5 Restoration of p53 knockdown-associated JAK2 downregulation improves IFN-ɣ-inducible PD-L1 expression. a Immunoblot of three melanoma cell lines containing either an inducible TP53-targeting or a scr shRNA expression vector. IFN-ɣ treatment was for 48 h. b, c Linear regression analyses of JAK2 mRNA with CD274 mRNA (b; n = 347) or PD-L1 protein (c; n = 262). d M19-MEL and UACC-62 cells containing an inducible TP53-targeting shRNA vector were treated for 6 days with doxycycline with the last 2 days either in absence or presence of IFN-ɣ. After RNA isolation and cDNA generation, real-time quantitative PCR was performed for determination of TP53, JAK2 and CD274 mRNA expression. Relative expressions were calculated by the ΔΔCq method to the respective cell line sample without doxycycline and IFN-ɣ treatment. After log2 transformation, the means + SD of three independent experiments are depicted. Significant differences are indicated by stars (* < 0.05; ** < 0.01; paired t-test). e Two melanoma cell lines containing Doxycycline-inducible p53 shRNA were transduced with a JAK2 expression construct. Control cells and JAK2-overexpressing cells were incubated with doxycycline and treated with IFN-ɣ for 48 h as described before. Expression of indicated proteins was determined by immunoblot. ß-tubulin served as a loading control. p < 0.05 is regarded as statistically significant. DOX, doxycycline; scr, scramble; TPM, transcripts per million, ctrl, control. All blots are representative of two individual experimentsCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 75 references

Cited by

See all 153

Metadata

Authors
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D.
Affiliations
  • Comprehensive Cancer Center Mainfranken (DE)
  • Universitätsklinikum Würzburg (DE)
  • LMU Klinikum (DE)
  • University of Würzburg (DE)
Corresponding author
Thiem, Alexander
Venue
Journal of Experimental & Clinical Cancer Research
Published
2019-09-11
Volume
38
Issue
1
Pages
397-397
ISSN
  • 0392-9078 (ISSN-L)
  • 1756-9966
OpenAlex
W2972715430
Cited by
153
References
76
Citations by year
2026: 6 · 2025: 11 · 2024: 25 · 2023: 34 · 2022: 27 · 2021: 29 · 2020: 21
FWCI
8.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Experimental & Clinical Cancer Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Online Publication Service of Würzburg University (Würzburg University) (submittedVersion, cc-by)
Funders
  • Comprehensive Cancer Center Mainfranken (Clinician Scientist scholarship)
  • Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg (IZKF B-323)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
melanoma, PD-L1 expression, p53, interferon-gamma, immune checkpoint, TP53 mutation, JAK2, anti-PD-1 therapy, tumor immune microenvironment, p53 knockdown, interferon-gamma signaling, PD-L1, p53 status
MeSH terms
Gene Editing, Humans, Interferon-gamma, Melanoma, Biomarkers, Tumor, Signal Transduction, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Gene Targeting, RNA, Small Interfering, Cell Line, Tumor, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. https://app.cochat.ai/papers/10.1186/s13046-019-1403-9
The paper
Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019). IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-019-1403-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.